![]() ![]() TCR overlap analysis will be further performed to track potential clonotype changes. Our results showed patient samples after cycle 8 had less TCR templates and TCR rearrangements compared to those from the other three time points although no significant difference were found in maximum clonotype frequency or T-cell clonality. Furthermore, we performed the same sequencing on 18 SMM patients at different treatment time points including chemotherapy after cycle 8, 20, and 32. No difference of T-cell clonality was found from MM and SMM. Only MM baseline showed higher maximum clonotype frequency. 2017, 49(5):659-665), we found less TCR templates from both MM and SMM baseline based on size of TCRB repertoire, and less TCR rearrangements or unique clonotypes based on structure of TCRB repertoires. Compared to TCRB data from 280 normal control (Age > 40) PBMCs (Nat Genet. To evaluate T-cell diversity and clonality, we performed pipeline analysis by ImmunoAnalyzer from Adaptive Technology, and downloaded sequencing data with manual analysis by JMP13 software. Using baseline genomic DNA (PBMC) from 24 patients with SMM and 31 patients with MM, we performed next-generation sequencing on the Illumina NextSeq 500 platform by immunoSEQ TCRB Kits from Adaptive Biotechnology to quantitatively assay the complementarity determining region 3 (CDR3) of human T-cell receptor β (TCRβ) gene. In this study, we aimed to investigate if T-cell receptor (TCR) repertoire has clinical significance in MM or Smoldering MM (SMM) diagnosis or prognosis. We hypothesized that peripheral blood mononuclear cells (PBMCs) may replace tedious and invasive bone marrow biopsies as a biomarker. Multiple myeloma (MM) is a hematological malignancy mostly assessed by bone marrow involvement, so it is attractive to develop a method using peripheral blood. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |